3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
34
Neoplasms
10
Prostatic Neoplasms
6
Neoplasm Metastasis
6
Carcinoma, Ovarian Epithelial
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Ovarian Neoplasms
4
Lymphoma, Mantle-Cell
4
Lymphoma, Follicular
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms, Male
4
Stomach Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large-Cell, Anaplastic
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Carcinoma, Renal Cell
3
Burkitt Lymphoma
3
Wilms Tumor
2
Testicular Neoplasms
2
Teratoma
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Salivary Gland Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Interventions
Carboplatin
27
Paclitaxel
23
Cisplatin
22
Gemcitabine
17
pembrolizumab
15
Fluorouracil
9
Pemetrexed
8
Everolimus
8
Docetaxel
8
Cetuximab
8
Radiotherapy, Intensity-Modulated
7
Radiotherapy
7
130-nm albumin-bound paclitaxel
7
Sorafenib
6
Nivolumab
6
Bevacizumab
6
Axitinib
6
epothilone B
5
Sunitinib
5
Radiation
5
Panitumumab
5
Cyclophosphamide
5
trebananib
4
reolysin
4
padeliporfin
4
lenvatinib
4
Irinotecan
4
Gefitinib
4
vosaroxin
3
volociximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma
×
ixabepilone
×
Clear all
NCT02915744
2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3
Completed
178 enrolled
37 charts